Background: Brain PET imaging with different tracers is mainly clinically used in the field of neurodegenerative diseases and brain tumors. In recent years, the potential usefulness of PET has also gained attention in the field of MS. In fact, MS is a complex disease and several processes can be selected as a target for PET imaging. The use of PET with several different tracers has been mainly evaluated in the research setting to investigate disease pathophysiology (i.e. phenotypes, monitoring of progression) or to explore its use a surrogate end-point in clinical trials. Results: We have reviewed PET imaging studies in MS in humans and animal models. Tracers have been grouped according to their pathophysiological targets (ie. tracers for myelin kinetic, neuroinflammation, and neurodegeneration). The emerging clinical indication for brain PET imaging in the differential diagnosis of suspected tumefactive demyelinated plaques as well as the clinical potential provided by PET images in view of the recent introduction of PET/MR technology are also addressed. Conclusion: While several preclinical and fewer clinical studies have shown results, fullscale clinical development programs are needed to translate molecular imaging technologies into a clinical reality that could ideally fit into current precision medicine perspectives. Keywords: Multiple sclerosis, Positron emission tomography, Neuroinflammation, TSPO, Amyloid, Tumefactive multiple sclerosis

Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers

Bauckneht, Matteo;Capitanio, Selene;Raffa, Stefano;Roccatagliata, Luca;Pardini, Matteo;Lapucci, Caterina;Sambuceti, Gianmario;Inglese, Matilde;Nobili, Flavio;Morbelli, Silvia
2019

Abstract

Background: Brain PET imaging with different tracers is mainly clinically used in the field of neurodegenerative diseases and brain tumors. In recent years, the potential usefulness of PET has also gained attention in the field of MS. In fact, MS is a complex disease and several processes can be selected as a target for PET imaging. The use of PET with several different tracers has been mainly evaluated in the research setting to investigate disease pathophysiology (i.e. phenotypes, monitoring of progression) or to explore its use a surrogate end-point in clinical trials. Results: We have reviewed PET imaging studies in MS in humans and animal models. Tracers have been grouped according to their pathophysiological targets (ie. tracers for myelin kinetic, neuroinflammation, and neurodegeneration). The emerging clinical indication for brain PET imaging in the differential diagnosis of suspected tumefactive demyelinated plaques as well as the clinical potential provided by PET images in view of the recent introduction of PET/MR technology are also addressed. Conclusion: While several preclinical and fewer clinical studies have shown results, fullscale clinical development programs are needed to translate molecular imaging technologies into a clinical reality that could ideally fit into current precision medicine perspectives. Keywords: Multiple sclerosis, Positron emission tomography, Neuroinflammation, TSPO, Amyloid, Tumefactive multiple sclerosis
File in questo prodotto:
File Dimensione Formato  
Bauckneht_et_al-2019-EJNMMI_Radiopharmacy_and_Chemistry.pdf

accesso aperto

Tipologia: Documento in versione editoriale
Dimensione 2.56 MB
Formato Adobe PDF
2.56 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/943324
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 12
social impact